{"url_path":"/sec/nwbo/8-k/2026-07-20/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1072379/0001104659-26-084743-index.html","accession_number":"0001104659-26-084743","cik":"0001072379","ticker":"NWBO","issuer_name":"NORTHWEST BIOTHERAPEUTICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1072379/0001104659-26-084743-index.html","primary_entity_key":"0001072379","primary_entity_name":"NORTHWEST BIOTHERAPEUTICS INC"},"word_count":303,"has_tables":true,"body_markdown":"false\n0001072379\n\n0001072379\n\n2026-07-17\n2026-07-17\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWASHINGTON, D.C. 20549\n\n \n\nFORM 8-K\n\n \n\nCURRENT REPORT\n\nPURSUANT TO SECTION 13 OR 15(d) OF THE\n\nSECURITIES EXCHANGE ACT OF 1934\n\n \n\nDate of report (Date of earliest event reported):\nJuly 17, 2026\n\n \n\nNorthwest Biotherapeutics, Inc.\n\n(Exact name of registrant as specified in\nits charter)\n\n \n\nDelaware\n \n0-35737\n \n94-3306718\n\n(State or other jurisdiction\n \n(Commission\n \n(IRS Employer\n\nof incorporation)\n \nFile Number)\n \nIdentification No.)\n\n \n\n4800 Montgomery Lane, Suite 800\n\nBethesda, Maryland 20814\n\n(Address of Principal Executive Offices)\n\n \n\n(240) 497-9024\n\n(Registrant’s telephone number, including\narea code)\n\n \n\n(Former Name or Former Address, if Changed\nSince Last Report)\n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction\nA.2. below):\n\n \n\n¨\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n¨\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.l4a-12)\n\n \n\n¨\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n¨\nPre-commencement communications pursuant to Rule l3e-4(c) under the Exchange Act (17 CFR 240. l3e-4(c))\n\n \n\n**Title of each class:**\n \n**Trading Symbol(s)**\n \n**Name of each exchange on which\nregistered:**\n\nCommon Stock, par value, $0.001 per share\n \nNWBO\n \nOTCQB\n\n \n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405\nof this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240. l2b-2 of this chapter).\n\n \n\nEmerging\nGrowth Company ¨\n\n** **\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨"}